2024-03-28T23:02:33Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_AA60ECC5901D
2024-03-23T02:49:04Z
openaire
documents
urnserval
serval:BIB_AA60ECC5901D
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab.
10.1016/j.ctrv.2017.10.002
000424071000005
29156447
Peters
S.
author
Kerr
K.M.
author
Stahel
R.
author
article
review
2018-01
Cancer treatment reviews
1532-1967
0305-7372
journal
62
39-49
Antibodies, Monoclonal, Humanized/therapeutic use
Antineoplastic Agents, Immunological/therapeutic use
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Non-Small-Cell Lung/immunology
Carcinoma, Non-Small-Cell Lung/pathology
Humans
Lung Neoplasms/drug therapy
Lung Neoplasms/immunology
Lung Neoplasms/pathology
Programmed Cell Death 1 Receptor/antagonists & inhibitors
Programmed Cell Death 1 Receptor/immunology
Anti-PD-1 antibody
Non–small cell lung cancer
PD-L1
Pembrolizumab
eng
60_published
true
peer-reviewed
Publication types: Journal Article ; Review
Publication Status: ppublish
https://serval.unil.ch/notice/serval:BIB_AA60ECC5901D
https://serval.unil.ch/resource/serval:BIB_AA60ECC5901D.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_AA60ECC5901D7
Copying allowed only for non-profit organizations